Prostate cancer is the most common cancer among men in the US – second only to non-melanoma skin cancer. Prostate cancer is more common in men over age 50.
MSK doctors have led pivotal studies that have changed the way prostate cancer is treated.
More than 90 percent of prostate cancers are found at an early stage when they're still within the prostate gland. Two tests commonly used to screen for prostate cancer are the prostate-specific antigen (PSA) test and the digital rectal exam (DRE). But neither test, either alone or in combination, can give you a certain diagnosis of prostate cancer. For that, Memorial Sloan Kettering (MSK) specialists need to:
The treatment options available to you depend on the nature of your prostate cancer. Men with prostate cancer generally fall into one of the following disease categories:
MSK's experts specialize in a number of treatment options, including:
MSK doctors have led pivotal studies that have changed the way prostate cancer is treated. For example, MSK researchers contributed to the successful development of the targeted drugs abiraterone acetate and enzalutamide for men with advanced prostate cancer. MSK is also the coordinating center for the Prostate Cancer Clinical Trials Consortium, a collaboration among 13 leading centers focused on early drug development and clinical trial design.
Men treated for prostate cancer may experience significant side effects. MSK's follow-up care team offers strategies to help you overcome or cope with problems, maintain a good quality of life and regain your sense of self. For men who experience changes in sexual and reproductive health, our Male Sexual and Reproductive Medicine Program can help you adjust to life during and after cancer treatment.
For more information about treatment for prostate cancer, please visit https://www.mskcc.org/cancer-care/types/prostate.> Learn More: Search by Cancer Type at MSK
© 2017 Memorial Sloan Kettering Cancer Center
WebMD does not endorse any specific product, service, or treatment.